InSphero announces the launch of the MASH CALL Initiative for fast and reliable identification and comparison of therapeutic candidates for the clinical treatment of MASH.
InSphero announces the launch of the MASH CALL Initiative for fast and reliable identification and comparison of therapeutic candidates for the clinical treatment of MASH.
InSphero Launches New Website Showcasing “The Model of Excellence™” Empowering Breakthroughs in 3D In Vitro Therapies
InSphero and Darwin Microfluidics signed distribution agreement to facilitate purchasing InSphero’s 3D in vitro products within the European Union Zurich, Switzerland – September 7, 2023
InSphero and Advanced BioMatrix signed a distribution agreement to expand the application range in 3D cell culture into scaffold-based models Zurich, Switzerland – August 8,
InSphero AG and Cosmo Bio Co., Ltd Enter into Strategic Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan Zurich, Switzerland and Tokyo, Japan -
The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models
InSphero and Bionova Supplies signed a distribution agreement to accelerate the development of spheroid and organoid cultures in India April 25, 2023 | Schlieren, Switzerland
Eurostars-funded REPRINT consortium reaches milestones with evidence of complete tumor regression induced by dendritic cell reprogramming Schlieren, Switzerland | 11 April 2023 InSphero announces today, together
ZEISS Ventures invests in InSphero to further drive 3D cell culture research Oberkochen, Germany; Schlieren, Switzerland | 31 March 2023 ZEISS is investing in life
Ready to unlock the full potential of 3D in vitro? Help us better understand your challenges and interests, and let's get started!
USA and Canada
Phone : +1 908-864-1550
TechPlace, 74 Orion St., Brunswick, ME 04011 USA
Europe and Rest of World
Phone : +41 44 515 04 90
Wagistrasse 27A, 8952, Schlieren, Switzerland